Connor Clark & Lunn Investment Management Ltd. Has $19.13 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 46.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 429,687 shares of the company’s stock after purchasing an additional 135,650 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.93% of Omnicell worth $19,130,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Smartleaf Asset Management LLC grew its holdings in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp grew its holdings in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. grew its holdings in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares during the period. Redmond Asset Management LLC grew its holdings in Omnicell by 0.3% in the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock worth $5,396,000 after purchasing an additional 371 shares during the period. Finally, Curi RMB Capital LLC grew its holdings in Omnicell by 0.7% in the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock worth $3,872,000 after purchasing an additional 651 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Benchmark reiterated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Wells Fargo & Company reduced their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Omnicell has an average rating of “Hold” and an average target price of $52.33.

Omnicell Stock Down 3.2 %

Omnicell stock opened at $32.28 on Friday. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The stock has a market cap of $1.51 billion, a PE ratio of 119.56, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The firm’s 50-day simple moving average is $40.96 and its 200 day simple moving average is $43.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.